Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with untreated mild-to-moderate essential hypertension, clinically diagnosed according to the World Health Organization criteria (systolic blood pressure =140-179 mm Hg and/or diastolic blood pressure =90-109 mm Hg on 3 consecutive occasions; standardized after 5 minutes in sitting position)~* Patients with newly diagnosed essential hypertension or previously treated patients from whom antihypertensive therapy can be safely withdrawn for the duration of the study.~* 18 to 65 years of age, males and non-reproductive females (surgically sterilized or post-menopausal)~* Written informed consent~* Patient is willing and able to comply with all trial requirements~Exclusion Criteria:~* Secondary hypertension~* Severe essential hypertension~* Current pharmacological treatment that could affect blood pressure~* Significant renal insufficiency \[Serum creatinine \> 159 µmol/L (\> 1.8 mg/dl)\]~* History of cerebrovascular disease~* Type 1 Diabetes or poorly controlled Type 2 Diabetes~* Body mass index (BMI) \>32~* Total cholesterol \> 6.9 mmol/L (\> 266 mg/dl)~* Triglycerides \> 3.5 mmol/L ( \> 174.3 mg/dl)~* Autoimmune diseases or severe allergies~* Patients with a history of HIV infection, AIDS, hepatitis B or C, or other immunosuppressive disorders~* Current diagnosis or a history of malignancy~* Drug or alcohol abuse within the past 2 years~* Pregnancy or breastfeeding~* Present history of mental diseases~* Participation in any drug trial within three month of onset of current trial~* Previous participation in a clinical trial with a Qb based vaccine (DerQb, NicQb, AllQb)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 100 mcg CYT006-AngQb Healthy Volunteers (Type: EXPERIMENTAL): None
- 100 mcg CYT006-AngQb Hypertensives (Type: EXPERIMENTAL): None
- 300 mcg CYT006-AngQb Hypertensives (Type: EXPERIMENTAL): None
- Placebo Healthy Volunteers (Type: PLACEBO_COMPARATOR): None
- Placebo Hypertensives (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).